July 26, 2018
Eisai/Biogen’s beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat demonstrated a statistically significant reduction of brain amyloid load versus placebo at 18 months in patients with a mild form of Alzheimer’s disease (AD), according to US PII data. The detailed results...read more